Ditchcarbon
  • Contact
  1. Organizations
  2. ISU Abxis Co., Ltd.
Public Profile
Pharmaceutical Preparation Manufacturing
KR
updated 2 months ago

ISU Abxis Co., Ltd. Sustainability Profile

Company website

ISU Abxis Co., Ltd., a prominent player in the biotechnology sector, is headquartered in South Korea (KR) and operates extensively across Asia and beyond. Founded in 2004, the company has established itself as a leader in the development of innovative diagnostic solutions and therapeutic antibodies, catering to the growing demands of the healthcare industry. ISU Abxis is renowned for its cutting-edge products, including monoclonal antibodies and diagnostic kits, which are distinguished by their high specificity and reliability. The company’s commitment to research and development has led to significant advancements in immunology and molecular diagnostics, positioning it as a trusted partner in the global market. With a focus on quality and innovation, ISU Abxis continues to achieve notable milestones, solidifying its reputation as a key contributor to the biotechnology landscape.

DitchCarbon Score

How does ISU Abxis Co., Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

20

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

34

Industry Benchmark

ISU Abxis Co., Ltd.'s score of 20 is lower than 83% of the industry. This can give you a sense of how well the company is doing compared to its peers.

17%

Let us know if this data was useful to you

ISU Abxis Co., Ltd.'s reported carbon emissions

ISU Abxis Co., Ltd., headquartered in South Korea (KR), currently does not have available carbon emissions data for the most recent year. As a result, there are no specific figures regarding their total emissions, which would typically encompass Scope 1, Scope 2, and Scope 3 emissions. Additionally, ISU Abxis has not outlined any reduction targets or commitments related to climate initiatives, such as those from the Science Based Targets initiative (SBTi) or other recognised climate pledges. The absence of documented reduction initiatives suggests that the company may still be in the early stages of developing a comprehensive climate strategy. Given the lack of emissions data and formal commitments, ISU Abxis Co., Ltd. appears to have opportunities for enhancing its climate action framework and establishing measurable targets in line with industry standards.

How Carbon Intensive is ISU Abxis Co., Ltd.'s Industry?

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. ISU Abxis Co., Ltd.'s primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

How Carbon Intensive is ISU Abxis Co., Ltd.'s Location?

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for ISU Abxis Co., Ltd. is in KR, which we do not have grid emissions data for.

ISU Abxis Co., Ltd.'s Climate Goals (2030 & 2050)

Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.

ISU Abxis Co., Ltd. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Compare ISU Abxis Co., Ltd.'s Emissions with Industry Peers

Genzyme Corporation, Inc.

US
•
Pharmaceutical Preparation Manufacturing
Updated 3 months ago

Samsung Biologics

KR
•
Pharmaceutical Preparation Manufacturing
Updated about 1 month ago

Actelion Pharmaceuticals Ltd

CH
•
Research and development services (73)
Updated about 1 month ago

Amicus

US
•
Pharmaceutical Preparation Manufacturing
Updated 27 days ago

Pfizer

US
•
Pharmaceutical Preparation Manufacturing
Updated about 1 month ago

Eli Lilly and Company

GB
•
Pharmaceutical Preparation Manufacturing
Updated 22 days ago

Let us know if this data was useful to you

Usage Policy

You're welcome to quote or reference data from this page, but please include a visible link back to this URL.

Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.

See our License Agreement for more details.

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v251209.2
[email protected]+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
UL Solutions verification badge
CDP logo
Gartner Cool Vendor 2025 badge
Available onAWS Marketplace logo
ProductPortalScope 3 Tool FunctionalityDataIntegrationsPricing
CustomersHaleonGrant ThorntonHikmaRead all stories
Use CaseSBTi-aligned baselining & progress trackingSupplier EngagementClimate-informed sourcing strategyEmission ReportingSustainable Finance
ResourcesCalculation MethodologyDocumentationBlogFAQOrganizationsIndustriesSBTI APITrust CentreChangelogWhitepaper
AboutTeamCareersLicense AgreementPrivacy